NSPR vs. NYXH, ZIMV, SMTI, SNWV, STIM, CATX, TCMD, NVRO, SGHT, and DRTS
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include Nyxoah (NYXH), ZimVie (ZIMV), Sanara MedTech (SMTI), SANUWAVE Health (SNWV), Neuronetics (STIM), Perspective Therapeutics (CATX), Tactile Systems Technology (TCMD), Nevro (NVRO), Sight Sciences (SGHT), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.
InspireMD vs. Its Competitors
InspireMD (NYSE:NSPR) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
InspireMD has a net margin of -413.96% compared to Nyxoah's net margin of -1,043.93%. Nyxoah's return on equity of -51.68% beat InspireMD's return on equity.
InspireMD has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
InspireMD has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.
InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 83.67%. Nyxoah has a consensus target price of $14.50, suggesting a potential upside of 87.10%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than InspireMD.
44.8% of InspireMD shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Nyxoah received 37 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 73.68% of users gave Nyxoah an outperform vote while only 4.95% of users gave InspireMD an outperform vote.
In the previous week, Nyxoah had 6 more articles in the media than InspireMD. MarketBeat recorded 7 mentions for Nyxoah and 1 mentions for InspireMD. Nyxoah's average media sentiment score of 0.79 beat InspireMD's score of 0.00 indicating that Nyxoah is being referred to more favorably in the news media.
Summary
Nyxoah beats InspireMD on 10 of the 17 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
This page (NYSE:NSPR) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy NSPR Stock Free NSPR Stock Alerts